RPI's Jacob Lee Signs in Switzerland
Swiss man returns to Philadelphia hospital after life-changing double hand transplant
29-year-old Luka Krizanac from Switzerland received a double hand transplant at Penn Medicine in Philadelphia, Pennsylvania in late 2024, 17 years after losing his hands and feet to an infection that turned into sepsis. Luka visited the Hospital of the University of Pennsylvania again this June and says the miracle surgery has changed his and his family's life.
1:25
Now Playing
Paused
Ad Playing
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
RPI's Jacob Lee Signs in Switzerland
Swiss man returns to Philadelphia hospital after life-changing double hand transplant 29-year-old Luka Krizanac from Switzerland received a double hand transplant at Penn Medicine in Philadelphia, Pennsylvania in late 2024, 17 years after losing his hands and feet to an infection that turned into sepsis. Luka visited the Hospital of the University of Pennsylvania again this June and says the miracle surgery has changed his and his family's life. 1:25 Now Playing Paused Ad Playing
Business Wire
3 days ago
- Business Wire
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking
LISBON, Portugal--(BUSINESS WIRE)--Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus' lead candidate for colorectal cancer. 'This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.' Benoit Pinteur Share Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010's therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed by monocyte-derived dendritic cells (mMo-DCs), activating CD8+ T cells. These T cells induced apoptosis in both 2D and 3D colorectal cancer models and released anti-tumor cytokines (IFNγ and Granzyme B). These data reinforce the therapeutic potential of STC-1010. ' This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.' Benoit Pinteur, CSO of Brenus Pharma. ' We are proud to support Brenus with our cryopreserved 3D tumor models. This work illustrates how advanced in vitro systems can bring immunotherapies closer to clinical reality.' Jan Lichtenberg, CEO of InSphero. About Brenus Pharma Brenus Pharma unlocks the potential of immuno-oncology by generating first-in-class immunotherapies that initiate a multi-specific in vivo immune response against tumors. Their proprietary 'off-the-shelf' Stimulated-tumor-Ghost-Cells (SGC) platform mimics patients' tumor cells and makes them visible to the immune system to anticipate, target, and destroy these cells as they appear. Brenus aims to shift the oncology paradigm by making patients active participants in their treatment.
USA Today
3 days ago
- USA Today
Roman Josi diagnosed with POTS. What it means and when Predators captain could return
Roman Josi diagnosed with POTS. What it means and when Predators captain could return The Nashville Predators have released a statement regarding captain Roman Josi's recent diagnosis of postural orthostatic tachycardia syndrome. "Roman Josi was diagnosed with POTS (postural orthostatic tachycardia syndrome) toward the end of the 2024-25 season," the statement reads. "He has been undergoing treatment since that diagnosis and is progressing exceptionally well," In a recent interview with Blick, a Swiss digital media company, Josi revealed that he was diagnosed with POTS after investigating the after effects of a head injury. The injury occurred during a Feb. 25 game against the Florida Panthers, when Sam Bennett hit Josi into the wall, causing his head to hit the glass. What is POTS and when will Roman Josi return to Predators? After dealing with headaches, dizziness and lightheadedness, Josi said the diagnosis was made during a post-concussion check-up. POTS is a condition in which one suffers an increased heart rate after standing up and can be accompanied by dizziness, fatigue and brain fog, according to Johns Hopkins Medicine. Since his diagnosis, Josi has been given medicine for treatment and expects to be able to play the 2025-26 season. 'I've been feeling much better since then," he told Blick, via Google Translate. "I've regained the belief that I'll be 100 percent fit again and can fully attack with Nashville and the Swiss national team next winter.' The Predators' statement adds that the organization feels Josi will be fine to play in the 2025-26 season. "We concur with Roman that with continued management and treatment, he can return to the ice for the 2025-26 season and continue his elite hockey career," the statement read. Josi, who missed the final 25 games of the season with a concussion, scored nine goals and had 29 assists in 53 games for Nashville in 2024-25. The 35-year-old captain is the Predators' all-time leader in points (724) and games played (962). OLYMPIAN: Roman Josi to represent Switzerland, Juuse Saros on Finland roster for 2026 Olympics Predators reacquire Erik Haula The Predators have acquired forward Erik Haula from the New Jersey Devils in exchange for a fourth-round pick (2025) and defenseman Jeremy Hanzel. Haula, 34, scored 11 goals and 10 assists for the Devils last season. In his 12-year career as a winger and center, Haula has 153 goals and 184 goals in 759 games for seven different teams. The trade brings Haula back to Nashville, where he spent the 2020-21 season. That year, he scored nine goals and 12 assists in 51 games with the Predators before leaving in free agency for the Boston Bruins. Haula is in the final year of a three-year contract he signed with New Jersey in 2023. He is owed $3.15 million for the 2025-26 season, after which he will be an unrestricted free agent. After accounting for Haula's $3.1 million cap hit, the Predators will have $14.2 million in cap space for the 2025-26 season, according to PuckPedia. Alex Daugherty is the Predators beat writer for The Tennessean. Contact Alex at jdaugherty@ Follow Alex on X, the platform formerly called Twitter, @alexdaugherty1. Also check out our Predators exclusive Instagram page @tennessean_preds.
